Innovative Bowel Preparation: E-PLUS Trial Protocol Using Elobixibat Hydrate

Study Background and Research Question

Colorectal cancer (CRC) remains a major health concern in Japan and globally, with screening rates hindered by challenges in bowel preparation acceptability and efficacy. Standard regimens using polyethylene glycol (PEG) plus ascorbic acid are effective but often require large volumes and have unpalatable flavors, leading to poor compliance. Alternative regimens, such as sodium picosulfate (SP) with magnesium citrate (MC), are more tolerable but may offer less thorough cleansing and delayed onset, limiting their adoption for high-stakes screening (source: Hotta et al., 2024). Hotta et al. designed the E-PLUS trial to address whether combining elobixibat hydrate—a selective ileal bile acid transporter (IBAT) inhibitor—with SP/MC can achieve at least non-inferior bowel cleansing compared to the standard split-dose PEG/ascorbic acid regimen before outpatient colonoscopy, while also improving patient acceptability.

Key Innovation from the Reference Study

The central innovation of the E-PLUS trial is the integration of elobixibat hydrate into bowel preparation protocols. Elobixibat hydrate enhances colonic bile acid concentrations by inhibiting IBAT in the ileum, increasing water secretion and colonic motility—mechanistically distinct from osmotic or stimulant laxatives (source: Hotta et al., 2024). By pairing this mechanism with the established SP/MC regimen, the protocol seeks to maximize both cleansing efficacy and patient tolerability, potentially reducing the required fluid volume and mitigating the taste and discomfort barriers associated with high-volume PEG solutions.

Methods and Experimental Design Insights

The E-PLUS trial is structured as a phase III, multicenter, randomized, single-blind, noninferiority study. Key protocol parameters are as follows:

Protocol Parameters

• assay | Participant age | 40–69 years | Inclusion criteria for generalizability to typical colonoscopy population | source: paper
• assay | Test group intervention | SP/MC + elobixibat hydrate | Evaluates synergistic bowel cleansing with dual mechanism | source: paper
• assay | Control group intervention | Split-dose 2-L PEG + ascorbic acid | Standard of care for bowel preparation | source: paper
• assay | Sample size | 540 total patients (270 per group) | Sufficient power for noninferiority analysis | source: paper
• assay | Primary endpoint | Boston Bowel Preparation Scale (BBPS) score ≥ 6 | Quantifies bowel cleansing efficacy | source: paper
• assay | Secondary endpoints | Acceptability, adverse events, polyp/adenoma detection, cleansing time | Comprehensive assessment of tolerability and diagnostic yield | source: paper
• workflow_recommendation | Elobixibat hydrate dosing | 10 mg oral, single pre-procedure dose | Reflects dosing for bowel preparation in clinical practice | product_spec

Exclusion criteria include prior abdominal/pelvic surgery, pre-existing constipation, inflammatory bowel disease, or severe organ dysfunction, which may confound bowel motility or safety outcomes.

Core Findings and Why They Matter

Although the E-PLUS trial is a protocol paper and results are pending, the rationale for this design is grounded in the mechanistic potential of elobixibat hydrate to enhance bowel preparation. Inadequate bowel cleansing can reduce polyp and adenoma detection rates, increase the risk of missed CRC, and necessitate repeat procedures, amplifying cost and patient burden. By aiming to improve both efficacy (BBPS ≥ 6) and tolerability, the protocol seeks to address a major bottleneck in CRC screening completion (source: Hotta et al., 2024). The study's design also incorporates patient-reported outcomes on acceptability—a critical but often underrepresented metric in bowel preparation studies. If the combination regimen demonstrates noninferiority or superiority, it could shift clinical practice toward more patient-centered protocols, supporting higher screening uptake and potentially better CRC outcomes.

Comparison with Existing Internal Articles

Several advanced reviews provide context for the mechanistic and translational relevance of elobixibat hydrate beyond its emerging role in bowel preparation:

• "Elobixibat Hydrate: Advanced Applications in GI and Metab..." discusses the compound’s pharmacological properties and applications in chronic idiopathic constipation and metabolic disorders. It emphasizes the dual impact on GI motility and metabolic modulation, offering a mechanistic foundation for its repurposing in bowel preparation workflows.
• "Elobixibat Hydrate: Molecular Precision in Bile Acid Tran..." provides detailed insights into IBAT inhibition and the resulting changes in bile acid homeostasis, which underlie both therapeutic effects in constipation and the theoretical benefit for bowel cleansing protocols.
• "Elobixibat Hydrate: Mechanistic Innovation and Strategic ..." highlights translational workflows and experimental design strategies, supporting the feasibility of adapting elobixibat for novel clinical endpoints such as bowel preparation efficacy and metabolic outcomes.

These internal articles collectively establish a mechanistic and translational rationale that aligns with the E-PLUS trial's approach, reinforcing the scientific basis for the trial’s dual-mechanism regimen.

Limitations and Transferability

The E-PLUS trial is currently a protocol, so clinical efficacy and safety data remain to be reported. Additionally, the study population is restricted to adults aged 40–69 without severe comorbidities or prior abdominal surgery, limiting immediate generalizability to older, more comorbid, or surgically altered populations. The single-blind design (blinding only the endoscopist) could introduce bias in subjective endpoints like acceptability. Furthermore, while the mechanistic rationale for elobixibat hydrate is strong, real-world data on adverse event profiles and patient preferences in this combination context are not yet available (source: Hotta et al., 2024). Transferability to other populations or indications, such as patients with chronic idiopathic constipation or metabolic abnormalities in type 2 diabetes mellitus, will require further direct studies, though the pharmacological background is promising (source: internal_article).

Research Support Resources

Researchers interested in replicating or extending the E-PLUS trial workflow can source high-purity elobixibat hydrate (SKU C8720) from APExBIO for experimental and translational studies. This IBAT inhibitor is well-characterized for both GI and metabolic research, supporting standardized protocol development for bowel preparation or related mechanistic assays (source: product_spec). Its physicochemical properties—including high protein binding and rapid systemic clearance—enable focused study of local GI effects relevant to both constipation management and bowel cleansing protocols.